Why the study?
Does cilostazol improve secondary prevention of stroke and reduce hemorrhagic events in patients with previous stroke or TIA?
Does cilostazol improve secondary prevention of stroke and reduce hemorrhagic events in patients with previous stroke or TIA?
Cilostazol shows promise for secondary stroke prevention with a favorable bleeding profile, suggesting a potential need to update current guidelines, pending data from non-Asian populations.
No takes yet. Share an insight, caveat, or question.
Supports cilostazol as a potentially safer secondary stroke prevention option; leaves open.
Galyfos et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: